Table 6.
HPV prevalence and three common genotypes of noncancerous cervical samples in Iran’s neighbouring countries
| Country | HPV prevalence in healthy female subjects** (Type of patients) |
Three common genotypes | HPV genotyping assay | Reference |
|---|---|---|---|---|
| Turkey | 17.9% (patients with normal pap smear) |
HPV-16 (3.6%), | line blot assay | (30) |
| HPV-6 (2.6%), | ||||
| HPV-45 (2.2%) | ||||
| Pakistan (Punjab) |
4.74% (patients with normal cervical cytology) |
HPV-6 (25%), | the partial HPV L1 region sequencing | (31) |
| HPV-55 (22.9%), | ||||
| HPV-11 (20.8%) | ||||
| Qatar | 7.6% (patients with normal and abnormal cervical cytology) |
HPV-81 (34.5%), | real-time PCR and Sanger sequencing | (32) |
| HPV-11 (31.0%), | ||||
| HPV-35 (6.9%) | ||||
| Iraq (Kurdistan Region) | 12.5% (Patients with vaginal discharge) | HPV-16 (53.8%) | Conventional PCR | (33) |
| Kuwait | 2.4% (patients with normal cervical cytology) |
HPV-11 (22.5%), | PCR-based sequencing | (34) |
| HPV-81 (18.3%), | ||||
| HPV-61 (12.6%), | ||||
| The Kingdom of Bahrain | 9.8% (patients with normal pap smear) |
HPV-52 (1.4%), | PCR DNA enzyme immunoassay (PCR-DEIA) and LiPA25 system | (35) |
| HPV-16 (1.1%) | ||||
| HPV-31 (1.1%) | ||||
| HPV-51 (1.1%) |